{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T14:31:40Z","timestamp":1690554700288},"reference-count":88,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.ejso.2005.02.032","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T11:25:42Z","timestamp":1118748342000},"page":"807-816","source":"Crossref","is-referenced-by-count":5,"title":["Biochemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques"],"prefix":"10.1016","volume":"31","author":[{"given":"M.G.A.","family":"van Ijken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"van Etten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.L.M.","family":"ten Hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Guetens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H.W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.A.","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4Suppl 4","key":"10.1016\/j.ejso.2005.02.032_bib1","first-page":"3","article-title":"Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer","volume":"14","author":"Hryniuk","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejso.2005.02.032_bib2","first-page":"3993","article-title":"Development of a technic for isolated perfusion of the liver","volume":"61","author":"Ausman","year":"1961","journal-title":"N Y State J Med"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2005.02.032_bib4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00000658-196005000-00014","article-title":"Studies on abdominal organ perfusion for cancer chemotherapy","volume":"151","author":"Shingleton","year":"1960","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00000658-199612000-00011","article-title":"Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience","volume":"224","author":"Eggermont","year":"1996","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.ejso.2005.02.032_bib6","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","article-title":"Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial","volume":"14","author":"Eggermont","year":"1996","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2005.02.032_bib7","first-page":"539","article-title":"Dual role of tumor necrosis factor-alpha in angiogenesis","volume":"140","author":"Fajardo","year":"1992","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0959-8049(94)00512-5","article-title":"High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer","volume":"31A","author":"Lejeune","year":"1995","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.2910570508","article-title":"Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)","volume":"57","author":"Renard","year":"1994","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm0498-408","article-title":"Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma","volume":"4","author":"Ruegg","year":"1998","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib11","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1054\/bjoc.1999.1032","article-title":"Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion","volume":"82","author":"de Wilt","year":"2000","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2005.02.032_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.bjc.6600707","article-title":"Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion","volume":"88","author":"van Etten","year":"2003","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1054\/bjoc.1999.1027","article-title":"TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects","volume":"82","author":"van der Veen","year":"2000","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.ejso.2005.02.032_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/jnci\/80.13.1039","article-title":"Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study","volume":"80","author":"Spriggs","year":"1988","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ejso.2005.02.032_bib15","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1200\/JCO.1988.6.8.1328","article-title":"A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients","volume":"6","author":"Feinberg","year":"1988","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2005.02.032_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00002371-200007000-00015","article-title":"TNF registered in Europe: does TNF get a second chance?","volume":"23","author":"Eggermont","year":"2000","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00002371-200007000-00008","article-title":"Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model","volume":"23","author":"van Ijken","year":"2000","journal-title":"J Immunother"},{"issue":"1\u20132","key":"10.1016\/j.ejso.2005.02.032_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6690335","article-title":"Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats","volume":"80","author":"de Wilt","year":"1999","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2005.02.032_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1067\/msy.2001.110365","article-title":"Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer","volume":"129","author":"Bartlett","year":"2001","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib21","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.1998.16.4.1479","article-title":"Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver","volume":"16","author":"Alexander","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2005.02.032_bib22","first-page":"2357","article-title":"Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms","volume":"4","author":"Alexander","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejso.2005.02.032_bib23","first-page":"3062","article-title":"A phase I\u2013II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver","volume":"6","author":"Alexander","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2005.02.032_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1053\/ejso.1998.0623","article-title":"Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan","volume":"25","author":"Lindner","year":"1999","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2362.1999.00480.x","article-title":"Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases","volume":"29","author":"De Vries","year":"1999","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s10434-000-0268-6","article-title":"Systemic toxicity and cytokine\/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage","volume":"7","author":"Stam","year":"2000","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2005.02.032_bib27","article-title":"Celic axis infusion (MMC, CDDP, 5-FU) and aortic stop-flow infusion vs abdominal hypoxic perfusion (MMC) in UICC stage III\/IV pancreatic cancer-48 patients","volume":"6","author":"Aigner","year":"1993","journal-title":"Reg Cancer Treat"},{"key":"10.1016\/j.ejso.2005.02.032_bib28","first-page":"55","article-title":"Regional chemotherapy\u2014editorial review article","volume":"2","author":"Aigner","year":"1994","journal-title":"Reg Cancer Treat"},{"key":"10.1016\/j.ejso.2005.02.032_bib29","first-page":"6","article-title":"Pelvic stopflow infusion and hypoxic pelvic perfusion-techniques and pharmacokinetics","author":"Aigner","year":"1995","journal-title":"Reg Cancer Treat"},{"issue":"1","key":"10.1016\/j.ejso.2005.02.032_bib30","first-page":"73","article-title":"Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells","volume":"41","author":"Teicher","year":"1981","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.ejso.2005.02.032_bib31","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2005.02.032_bib32","first-page":"202","article-title":"A percutaneous aortic stop-flow infusion technique for regional cytotoxic therapy of the abdomen and pelvis","volume":"7","author":"Thompson","year":"1994","journal-title":"Reg Cancer Treat"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archsurg.1993.01420170067009","article-title":"Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique","volume":"128","author":"Turk","year":"1993","journal-title":"Arch Surg"},{"issue":"3","key":"10.1016\/j.ejso.2005.02.032_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/jsre.1995.1184","article-title":"Pharmacokinetic studies of intraaortic stop-flow infusion with 14C-labeled mitomycin C","volume":"59","author":"Averbach","year":"1995","journal-title":"J Surg Res"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejso.2004.03.016","article-title":"Balloon catheter hypoxic abdominal perfusion with mitomycin C and melphalan for locally advanced pancreatic cancer: a phase I\u2013II trial","volume":"30","author":"van IJken","year":"2004","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ejso.2004.03.015","article-title":"Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, melphalan and mitomycin C: a pharmacokinetic study in pigs","volume":"30","author":"van IJken","year":"2004","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib37","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0748-7983(98)93572-7","article-title":"Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer","volume":"24","author":"Lorenz","year":"1998","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF02307065","article-title":"Intraaortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers","volume":"2","author":"Averbach","year":"1995","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2005.02.032_bib39","article-title":"Aortic stopflow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulky peritoneal carcinomatosis-rationale and technique","volume":"6","author":"Aigner","year":"1993","journal-title":"Reg Cancer Treat"},{"key":"10.1016\/j.ejso.2005.02.032_bib40","first-page":"6","article-title":"Pelvic stopflow perfusion and hypoxic pelvic perfusion with MMC and melphalan for recurrent rectal cancer","volume":"7","author":"Aigner","year":"1994","journal-title":"Reg Cancer Treat"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s002800050918","article-title":"A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion","volume":"43","author":"Wanebo","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1046\/j.1463-1318.2003.00523.x","article-title":"Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer","volume":"5","author":"Wanebo","year":"2003","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ejso.2005.02.032_bib43","first-page":"67","article-title":"Advanced gastric cancer: review of regional chemotherapy trials and treatment strategies using stop-flow infusion","volume":"8","author":"Averbach","year":"1995","journal-title":"Reg Cancer Treat"},{"key":"10.1016\/j.ejso.2005.02.032_bib44","first-page":"88","article-title":"Intra-aorticstop-flow infusion with hypoxic abdominal perfusion in UICC stage III\/IV pancreatic carcinoma: report of a phase II study","volume":"9","author":"Fiorentini","year":"1996","journal-title":"Reg Cancer Treat"},{"issue":"8","key":"10.1016\/j.ejso.2005.02.032_bib45","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0959-8049(00)00073-3","article-title":"Regional chemotherapy in the treatment of advanced pancreatic cancer\u2014is it relevant?","volume":"36","author":"Lorenz","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2005.02.032_bib46","first-page":"1344","article-title":"Locoregional and systemic therapy in advanced pancreatic carcinoma","volume":"Suppl 2","author":"Gebauer","year":"1998","journal-title":"Arch Chir"},{"key":"10.1016\/j.ejso.2005.02.032_bib47","first-page":"339","article-title":"Letter to the editor","volume":"25","author":"Guadigni","year":"1999","journal-title":"Eur J Surg Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.ejso.2005.02.032_bib48","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.10754","article-title":"On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer","volume":"95","author":"McGinn","year":"2002","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2005.02.032_bib49","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s002689900605","article-title":"Palliative chemotherapy and radiotherapy for pancreatic cancer: is it worthwhile?","volume":"23","author":"van der Schelling","year":"1999","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib50","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2005.02.032_bib51","doi-asserted-by":"crossref","unstructured":"Van IJken MG, Van Etten B, Guetens G, De Bruijn EA, Ten Hagen TLM, Wiggers Th, et al. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I\u2013II trial. Eur J Surg Oncol. In press.","DOI":"10.1016\/j.ejso.2005.06.004"},{"issue":"3","key":"10.1016\/j.ejso.2005.02.032_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF02049476","article-title":"Surgery for local recurrence of rectal carcinoma","volume":"39","author":"Wiggers","year":"1996","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib53","first-page":"3669","article-title":"Treatment of unresectable malignant abdominal, pelvic and thoracic tumors using abdominal pelvic and thoracic stop-flow chemotherapy","volume":"21","author":"Chrysos","year":"2001","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejso.2005.02.032_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00008390-200302000-00009","article-title":"Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study","volume":"13","author":"Guadagni","year":"2003","journal-title":"Melanoma Res"},{"issue":"8","key":"10.1016\/j.ejso.2005.02.032_bib55","first-page":"252","article-title":"Neoadjuvant therapy with high dose chemotherapy via isolated pelvic intra-abdominal perfusion with bone marrow stem cell support for advanced endometrial cancer","volume":"86","author":"Delaney","year":"2003","journal-title":"Med Health R I"},{"issue":"1","key":"10.1016\/j.ejso.2005.02.032_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00520-002-0355-2","article-title":"Curative and palliative aspects of regional chemotherapy in combination with surgery","volume":"11","author":"Muller","year":"2003","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2005.02.032_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/bja\/88.2.193","article-title":"Cardiovascular effects of simultaneous occlusion of the inferior vena cava and aorta in patients treated with hypoxic abdominal perfusion for chemotherapy","volume":"88","author":"Hofland","year":"2002","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1016\/j.ejso.2005.02.032_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1096-9098(199601)61:1<17::AID-JSO5>3.0.CO;2-V","article-title":"Vascular complications of total abdominal perfusion and aortic stop-flow infusion","volume":"61","author":"Klein","year":"1996","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib59","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00000658-199812000-00007","article-title":"Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs","volume":"228","author":"van IJken","year":"1998","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ejso.2005.02.032_bib60","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/bjs.1800800820","article-title":"Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion","volume":"80","author":"Hill","year":"1993","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.ejso.2005.02.032_bib61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/path.1711760310","article-title":"VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha","volume":"176","author":"Renard","year":"1995","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/ejso.2000.0951","article-title":"Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer","volume":"26","author":"Kornmann","year":"2000","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib63","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/annonc\/mdg207","article-title":"Adjuvant therapy in pancreatic cancer: historical and current perspectives","volume":"14","author":"Neoptolemos","year":"2003","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib64","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00000658-198712000-00001","article-title":"A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases","volume":"206","author":"Chang","year":"1987","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2005.02.032_bib65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/lt.500050113","article-title":"Management of hepatic metastases","volume":"5","author":"Choti","year":"1999","journal-title":"Liver Transpl Surg"},{"issue":"3","key":"10.1016\/j.ejso.2005.02.032_bib66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1634\/theoncologist.4-3-197","article-title":"Surgical treatment and other regional treatments for colorectal cancer liver metastases","volume":"4","author":"Yoon","year":"1999","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ejso.2005.02.032_bib67","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1470-2045(00)00419-8","article-title":"Hepatic-arterial chemotherapy","volume":"2","author":"Kemeny","year":"2001","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2005.02.032_bib68","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/1097-0142(19920115)69:2<557::AID-CNCR2820690246>3.0.CO;2-Q","article-title":"Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases","volume":"69","author":"Mavligit","year":"1992","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib69","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/bjc.1990.404","article-title":"A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats","volume":"62","author":"Marinelli","year":"1990","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2005.02.032_bib70","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/bjc.1991.466","article-title":"Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion","volume":"64","author":"Marinelli","year":"1991","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejso.2005.02.032_bib71","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/ejso.2002.1328","article-title":"Isolated liver perfusion for non-resectable liver tumours: a review","volume":"28","author":"Christoforidis","year":"2002","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2005.02.032_bib72","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/bjc.1991.242","article-title":"Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer","volume":"64","author":"Marinelli","year":"1991","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ejso.2005.02.032_bib73","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/bjc.1997.248","article-title":"Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan","volume":"75","author":"Borel Rinkes","year":"1997","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2005.02.032_bib74","first-page":"1539","article-title":"Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver","volume":"82","author":"Vahrmeijer","year":"2000","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2005.02.032_bib75","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/bjs.4308","article-title":"Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver","volume":"90","author":"Rothbarth","year":"2003","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib76","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.5-5-416","article-title":"Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver","volume":"5","author":"Alexander","year":"2000","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ejso.2005.02.032_bib77","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.jjco.a023243","article-title":"Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver","volume":"26","author":"Marinelli","year":"1996","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejso.2005.02.032_bib78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-642-80460-1_11","article-title":"Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans","volume":"147","author":"de Vries","year":"1998","journal-title":"Recent Results Cancer Res"},{"issue":"4","key":"10.1016\/j.ejso.2005.02.032_bib79","first-page":"784","article-title":"Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion","volume":"7","author":"Lans","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejso.2005.02.032_bib80","first-page":"45","article-title":"Use of tumor necrosis factor in isolated hepatic perfusion","volume":"44","author":"Fraker","year":"1994","journal-title":"Circ Shock"},{"issue":"2C","key":"10.1016\/j.ejso.2005.02.032_bib81","first-page":"1811","article-title":"Tumor necrosis factor and isolated hepatic perfusion: from preclinical tumor models to clinical studies","volume":"23","author":"de Vries","year":"2003","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ejso.2005.02.032_bib82","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archsurg.138.3.325","article-title":"Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study","volume":"138","author":"Savier","year":"2003","journal-title":"Arch Surg"},{"issue":"33","key":"10.1016\/j.ejso.2005.02.032_bib83","first-page":"776","article-title":"Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure","volume":"47","author":"Eggermont","year":"2000","journal-title":"Hepatogastroenterology"},{"issue":"24","key":"10.1016\/j.ejso.2005.02.032_bib84","first-page":"1961","article-title":"Efficacy of repeated percutaneous isolated liver chemoperfusion in local control of unresectable hepatocellular carcinoma","volume":"45","author":"Ku","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ejso.2005.02.032_bib85","doi-asserted-by":"crossref","unstructured":"van Etten B, Brunstein F, van IJken MGA, Marinelli AWKS, Verhoef C, van der Sijp JRM, et al. Isolated hypoxic hepatic perfusion (IHHP) with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques. a phase I\u2013II study. Am Surg Oncol 2004;11(6):598\u2013605.","DOI":"10.1245\/ASO.2004.09.021"},{"issue":"9","key":"10.1016\/j.ejso.2005.02.032_bib86","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ejso.2003.08.004","article-title":"An experimental minimally invasive perfusion technique for the treatment of liver metastases","volume":"29","author":"Rothbarth","year":"2003","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2005.02.032_bib87","doi-asserted-by":"crossref","unstructured":"Brunstein F, Hoving S, Seynhaeve ALB, Van Tiel ST, De Boeck G, De Bruijn EA, et al. Synergistic anti-tumor activity of histamine plus melphalan in the isolated limb perfusion (ILP)\u2014preclinical studies. J Natl Cancer Inst 2004;96(21):1603\u201310.","DOI":"10.1093\/jnci\/djh300"},{"key":"10.1016\/j.ejso.2005.02.032_bib88","unstructured":"Brunstein F, Seynhaeve ALB, Van Tiel ST, De Boeck G, De Bruijn EA, Eggermont AMM, et al. Synergistic antitumor activity of histamine plus melphalan in the isolated hepatic perfusion (IHP) without increased liver toxicity. Submitted for publication."}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798305001125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798305001125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T18:34:53Z","timestamp":1586284493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798305001125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0748798305001125"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2005.02.032","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}